Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck, Eva Ciruelos, Guy Jerusalem et al. · Nature Medicine · 2024
Full textCC BY
Oncology
Filters3 filters applied
Status
- Expression of concern
- Corrected
- No notice
- Not checked
- From publisher notices and Retraction Watch. Not checked means nobody has looked yet.
Year
Readable here
Study type
25 papersQuestions on this topic
Corrected Corrected First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A. Azad, Nobuaki Matsubara et al. · Nature Medicine · 2023 · Randomised trial
Full textCC BY
Corrected Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Joseph Tintelnot, Yang Xu, Till R. Lesker et al. · Nature · 2023
Full textCC BY
Corrected Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Xianjing Chu, Wentao Tian, Ziqi Wang et al. · Molecular Cancer · 2023 · Review
Full textCC BY
Corrected Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment
Gregor Werba, Daniel Weissinger, Emily A. Kawaler et al. · Nature Communications · 2023
Full textCC BY
Corrected Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia
Ester Gil Vazquez, Nadia Nasreddin, Gabriel N. Valbuena et al. · Cell Stem Cell · 2022
Full textCC BY
Corrected Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome
Hua Su, Fei Yang, Rao Fu et al. · Nature · 2022
Full textCC BY
Corrected Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
Juanjuan Yuan, Ting Cai, Xiaojun Zheng et al. · Protein & Cell · 2021
Full textCC BY
Corrected Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma
Phuong H. D. Nguyen, Siming Ma, Cheryl Z. J. Phua et al. · Nature Communications · 2021
Full textCC BY
Corrected NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis
Xu-Sheng Liu, Lu-Meng Zhou, Ling-Ling Yuan et al. · Frontiers in Immunology · 2021
Full textCC BY
Corrected Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Yaohui Gao, Dexi Bi, Ruting Xie et al. · Signal Transduction and Targeted Therapy · 2021
Full textCC BY
Corrected Cancer-Related Fatigue: Causes and Current Treatment Options
Melissa S.Y. Thong, Cornelis J. F. van Noorden, Karen Steindorf et al. · Current Treatment Options in Oncology · 2020 · Review
Full textCC BY
Corrected The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
Akram Pourshams, Sadaf G Sepanlou, Kevin S Ikuta et al. · The Lancet Gastroenterology & Hepatology · 2019
Full textCC BY
Corrected Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik et al. · Scientific Reports · 2019
Full textCC BY
Corrected A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Zhichen Sun, Zhenhua Ren, Kaiting Yang et al. · Nature Communications · 2019
Full textCC BY
Corrected Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Qing Zhang, Haixu Zhang, Jiage Ding et al. · Journal of Immunology Research · 2018
Full textCC BY
Corrected miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
Qian Huang, Jiajia Xia, Lei Wang et al. · Journal of Hematology & Oncology · 2018
Full textCC BY
Corrected LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer
T. Boulding, R. D. McCuaig, A. Tan et al. · Scientific Reports · 2018
Full textCC BY
Corrected The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016
Preet K Dhillon, Prashant Mathur, A Nandakumar et al. · The Lancet Oncology · 2018
Full textCC BY
Corrected MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state
Vittoria Poli, Luca Fagnocchi, Alessandra Fasciani et al. · Nature Communications · 2018
Full textCC BY